News and
Announcements
Stay up to date on all our news and market announcements.
TruScreen FY2025 Preliminary Results
Truscreen Group Limited (NZX/ASX: TRU) (the Company) has released its preliminary unaudited financial results for the year ended 31 March 2025.
Published Saudi Arabia study confirmed TruScreen’s high sensitivity and specificity vs pap smear
Published Saudi Arabia study confirms TruScreen’s high sensitivity and specificity compared to pap smear.
TruScreen re-enters India, appointing Renovate Biologicals Pvt Ltd as distributor
TruScreen re-enters India and appoints Renovate Biologicals Pvt Ltd to distribute its AI enabled TruScreen cervical cancer screening system in India.
TruScreen to Present at Singapore Healthcare Day Forum
Marty Dillon, TruScreen CEO, is presenting the company’s innovative AI enabled cervical cancer screening technology at the Singapore Healthcare Day Forum.
TruScreen Investor Presentation March 2025
TruScreen is pleased to share an updated Investor Presentation as at March 2025.
Key Markets Update and Revenue Guidance
TruScreen Group Limited (NZX/ASX:TRU) is pleased to provide an update of its key markets and target markets.
TruScreen Signs MOU with Hangzhou Dalton Bioscience to Expand HPV Product Offerings
TruScreen Group Limited has signed a non-binding Memorandum of Understanding (“MOU”) with Hangzhou Dalton Bioscience Limited (“DaltonBio”), a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening.
TruScreen appoints a distributor in Indonesia
TruScreen appoints PT Mawar Mitra Medika to distribute its AI enabled TruScreen cervical cancer screening system in Indonesia.
TruScreen Presents at WHO Global AI Collaboration Meeting
TruScreen had presented at a World Health Organisation (WHO) global meeting to further the use of AI technologies for screening of cervical cancer.
Sign up for regular
updates and
announcements.
Can’t see the form?
Email us at marketing@truscreen.com to subscribe